MicroPort® EP Launches Pressure-Sensing Pulsed Field Ablation Catheter, Expanding Its Multi-Energy Platform

Shanghai, China – November 23, 2025 — MicroPort® EP (Shanghai MicroPort EP MedTech Co., Ltd.) has announced the approval and launch of the PulseMagic™ TrueForce®, a single-use pressure-sensing pulsed field ablation (PFA) catheter, by China’s National Medical Products Administration (NMPA). This new device expands MicroPort® EP’s non-thermal ablation portfolio and marks a further step in the company’s development of a platform integrating cryoablation, radiofrequency (RF), and pulsed field energy.

PulseMagic™ TrueForce® is the first PFA catheter in its class in China equipped with both real-time pressure sensing and saline irrigation. The catheter is designed for use with MicroPort® EP’s Columbus® 3D cardiac mapping system, supporting controlled, consistent, and targeted ablation procedures.

Key features of the PulseMagic™ TrueForce® catheter include:

• Real-time pressure monitoring using strain gauge sensor technology to ensure stable catheter-tissue contact.
• Saline irrigation to support uniform energy delivery and lesion consistency.
• Integration with Columbus® 3D mapping for procedural visualization and improved workflow.
• Streamlined usability with an interface and handling experience consistent with the FireMagic™ TrueForce® RF catheter, helping to shorten the learning curve for physicians.

The product combines multiple technologies, pulsed field ablation, magnetic navigation, and pressure feedback, to provide physicians with greater precision and control during electrophysiology procedures.

Dr. Yiyong Sun, President of MicroPort® EP, commented:
“By introducing pressure sensing and visualization to the pulsed field ablation pathway, PulseMagic™ TrueForce® enhances precision and consistency in non-thermal cardiac ablation procedures. This is an important step in expanding our electrophysiology platform.”

MicroPort® EP continues to invest in R&D to build a scalable and innovative ecosystem across the three leading energy modalities, cryothermal, radiofrequency, and pulsed field, to deliver integrated interventional solutions for electrophysiology.

About MicroPort EverPace

Founded in 2010, MicroPort EverPace (Shanghai MicroPort EP MedTech Co., Ltd; SSE: 688351), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical devices company focusing on the development, manufacturing, and commercializing minimally invasive medical devices for the treatment of cardiac arrhythmia. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These solutions are used by hundreds of physicians at over 1100 hospitals over more than 30 countries. MicroPort EverPace strives to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.

More information is available at: www.everpace.com/en